Jürgen Wolf

28.3k total citations · 2 hit papers
139 papers, 5.4k citations indexed

About

Jürgen Wolf is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Jürgen Wolf has authored 139 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 65 papers in Oncology, 61 papers in Pulmonary and Respiratory Medicine and 33 papers in Pathology and Forensic Medicine. Recurrent topics in Jürgen Wolf's work include Lung Cancer Treatments and Mutations (58 papers), Lymphoma Diagnosis and Treatment (29 papers) and Lung Cancer Research Studies (22 papers). Jürgen Wolf is often cited by papers focused on Lung Cancer Treatments and Mutations (58 papers), Lymphoma Diagnosis and Treatment (29 papers) and Lung Cancer Research Studies (22 papers). Jürgen Wolf collaborates with scholars based in Germany, United States and France. Jürgen Wolf's co-authors include Volker Diehl, Roman K. Thomas, Reinhard Buettner, Daniel Ré, Andrea Staratschek‐Jox, Thomas Zander, Matthias Scheffler, Andreas H. Scheel, Anne M. Schultheis and Lukas C. Heukamp and has published in prestigious journals such as Journal of Clinical Investigation, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Jürgen Wolf

132 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial

2022 244 citations Vivek Subbiah, Jürgen Wolf et al. The Lancet Oncology profile →
Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial

2022 119 citations Alexander Drilon, Vivek Subbiah et al. Journal of Clinical Oncology profile →

Peers

Countries citing papers authored by Jürgen Wolf

Since Specialization

Citations

This map shows the geographic impact of Jürgen Wolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jürgen Wolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jürgen Wolf more than expected).

Fields of papers citing papers by Jürgen Wolf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jürgen Wolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jürgen Wolf. The network helps show where Jürgen Wolf may publish in the future.

Co-authorship network of co-authors of Jürgen Wolf

This figure shows the co-authorship network connecting the top 25 collaborators of Jürgen Wolf. A scholar is included among the top collaborators of Jürgen Wolf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jürgen Wolf. Jürgen Wolf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Early Metabolic Response by PET Predicts Sensitivity to Next-Line Targeted Therapy inEGFR-Mutated Lung Cancer with Unknown Mechanism of Acquired Resistance 2024 ·Journal of Nuclear Medicine ·Martin Schüler, J. Hense, Kaid Darwiche, Sebastian Michels, Hubertus Hautzel, Carsten Kobe, Smiths Lueong, Martin Metzenmacher, Thomas Herold, (unknown), (unknown), Alexander Drzezga, Dirk Theegarten, Felix Nensa, Jürgen Wolf, Ken Herrmann, Marcel Wiesweg	3
2	Frequency and functional characterization of fusion genes in squamous cell carcinoma of the lung 2023 ·Gene ·Christina Alidousty, A Becker, Elke Binot, Axel M. Hillmer, Sabine Merkelbach‐Bruse, Birgit Budde, (unknown), Gunter Rappl, Jürgen Wolf, Marie‐Lisa Eich, Ka‐Won Noh, Reinhard Buettner, Anne M. Schultheis	1
3	Durable Response With Sequential Tyrosine Kinase Inhibitor Treatment in a Patient With ROS1 Fusion–Positive Pancreatic Adenocarcinoma: A Case Report 2023 ·JCO Precision Oncology ·(unknown), Jana Fassunke, Michael Püsken, (unknown), Elke Binot, Anna Eisert, Rieke Fischer, Lucia Nogová, Richard Riedel, (unknown), (unknown), Matthias Scheffler, H. Schulz, (unknown), Thomas Zander, Sabine Merkelbach‐Bruse, Peter Schirmacher, Reinhard Büttner, Jürgen Wolf, Sebastian Michels	2
4	Selpercatinib in Patients With RET Fusion–Positive Non–Small-Cell Lung Cancer: Updated Safety and Efficacy From the Registrational LIBRETTO-001 Phase I/II Trial breakdown → 2022 ·Journal of Clinical Oncology ·Alexander Drilon, Vivek Subbiah, Oliver Gautschi, Pascale Tomasini, Filippo de Braud, Benjamin Solomon, Daniel S.W. Tan, Guzmán Alonso, Jürgen Wolf, Keunchil Park, Kōichi Goto, Victoria Soldatenkova, (unknown), Scott Barker, Tarun Puri, Aimee Bence Lin, Herbert H. Loong, Benjamin Besse	119
5	Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial breakdown → 2022 ·The Lancet Oncology ·Vivek Subbiah, Jürgen Wolf, Bhavana Konda, Hyunseok Kang, Alexander I. Spira, Jared Weiss, Masayuki Takeda, Yuichiro Ohe, Saad A. Khan, Kadoaki Ohashi, Victoria Soldatenkova, (unknown), Loretta Sullivan, Jennifer Wright, Alexander Drilon	244
6	Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study 2019 ·Clinical Cancer Research ·Daniel Morgensztern, Benjamin Besse, Laurent Greillier, Rafael Santana-Dávila, Neal Ready, Christine L. Hann, Bonnie S. Glisson, Anna F. Farago, Afshin Dowlati, Charles M. Rudin, Sylvestre Le Moulec, Satwant Lally, Sreeni Yalamanchili, Jürgen Wolf, Ramaswamy Govindan, David P. Carbone	229
7	Mechanisms of Primary Drug Resistance in FGFR1 -Amplified Lung Cancer 2017 ·Clinical Cancer Research ·Florian Malchers, Meryem S. Ercanoglu, (unknown), Roberta Castiglione, Verena Tischler, Sebastian Michels, Ilona Dahmen, Johannes Brägelmann, Roopika Menon, Johannes M. Heuckmann, Julie George, Sascha Ansén, Martin L. Sos, Alex Soltermann, Martin Peifer, Jürgen Wolf, Reinhard Büttner, Roman K. Thomas	41
8	PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4) 2017 ·Journal of Thoracic Oncology ·Gilberto de Castro, Daniel Shao-Weng Tan, Lucio Crinò, Yi‐Long Wu, Luis Paz‐Ares, Jürgen Wolf, Sarayut Lucien Geater, Sergey Orlov, Diego Cortinovis, Chong‐Jen Yu, Maximilian J. Hochmair, Alexis B. Cortot, Chun‐Ming Tsai, Denis Moro‐Sibilot, Rosario García Campelo, Fabrice Branle, Paramita Sen, Tracey McCulloch, Jean‐Charles Soria	8
9	P3.02a-025 PROs With Ceritinib Versus Chemotherapy in Patients With Previously Untreated ALK-rearranged Nonsquamous NSCLC (ASCEND-4) 2017 ·Journal of Thoracic Oncology ·Daniel Shao-Weng Tan, Jean‐Charles Soria, Gilberto de Castro, Yi‐Long Wu, Luis Paz‐Ares, Jürgen Wolf, Sarayut Lucien Geater, Sergey Orlov, Diego Cortinovis, Chong‐Jen Yu, Maximilian J. Hochmair, Alexis B. Cortot, Chun‐Ming Tsai, Denis Moro‐Sibilot, Rosario García Campelo, Fabrice Branle, Paramita Sen, (unknown), Tracey McCulloch, Lucio Crinò	2
10	Modulation of Biomarker Expression by Osimertinib: Results of the Paired Tumor Biopsy Cohorts of the AURA Phase I Trial 2017 ·Journal of Thoracic Oncology ·Kenneth S. Thress, Vivien N. Jacobs, Helen K. Angell, James Chih‐Hsin Yang, Lecia V. Sequist, Fiona Blackhall, Wu‐Chou Su, Martin Schüler, Jürgen Wolf, Kathryn A. Gold, Mireille Cantarini, J. Carl Barrett, Pasi A. Jänne	17
11	A Novel EGFR C797 Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture–Based Next-Generation Sequencing Assay 2016 ·Journal of Thoracic Oncology ·Roopika Menon, (unknown), (unknown), Sotirios Lakis, Kenneth S. Thress, Jürgen Wolf, Lukas C. Heukamp, Johannes M. Heuckmann, Frank Griesinger	25
12	Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas 2016 ·Modern Pathology ·Andreas H. Scheel, Manfred Dietel, Lukas C. Heukamp, Korinna Jöhrens, Thomas Kirchner, Simone Reu, Josef Rüschoff, Hans‐Ulrich Schildhaus, Peter Schirmacher, Markus Tiemann, Arne Warth, Wilko Weichert, Rieke Fischer, Jürgen Wolf, Reinhard Buettner	268
13	NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas 2015 ·International Journal of Cancer ·Lydia Meder, Katharina König, Luka Ozretić, Anne M. Schultheis, (unknown), Carsten P. Ade, Kerstin Albus, Diana Boehm, Ursula Rommerscheidt‐Fuss, Alexandra Florin, (unknown), Wolfgang Hartmann, Jürgen Wolf, Sabine Merkelbach‐Bruse, Martin Eilers, Sven Perner, Lukas C. Heukamp, Reinhard Buettner	141
14	A Modeling and Simulation Framework for Adverse Events in Erlotinib-Treated Non-Small-Cell Lung Cancer Patients 2015 ·The AAPS Journal ·Ahmed A. Suleiman, Sebastian Frechen, Matthias Scheffler, Thomas Zander, Lucia Nogová, Martin Köcher, Ulrich Jaehde, Jürgen Wolf, Uwe Fuhr	9
15	Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer 2013 ·Journal of Clinical Investigation ·Sampurna Chatterjee, Lukas C. Heukamp, (unknown), Jakob Schöttle, Caroline Wieczorek, Martin Peifer, (unknown), Mirjam Koker, Katharina König, Lydia Meder, Daniel Rauh, Reinhard Buettner, Jürgen Wolf, Rolf A. Brekken, Bernd Neumaier, Gerhard Christofori, Roman K. Thomas, Roland T. Ullrich	164
16	Diarrhea associated with afatinib: an oral ErbB family blocker 2013 ·Expert Review of Anticancer Therapy ·James Chih‐Hsin Yang, Noemı́ Reguart, Jana Barinoff, Jens Köhler, Martina Uttenreuther‐Fischer, Uz Stammberger, Dennis O’Brien, Jürgen Wolf, Ezra E.W. Cohen	88
17	Quantitative Analysis of Response to Treatment with Erlotinib in Advanced Non–Small Cell Lung Cancer Using ¹⁸F-FDG and 3′-Deoxy-3′-¹⁸F-Fluorothymidine PET 2011 ·Journal of Nuclear Medicine ·Deniz Kahraman, Matthias Scheffler, Thomas Zander, Lucia Nogová, Adriaan A. Lammertsma, Ronald Boellaard, Bernd Neumaier, Roland T. Ullrich, (unknown), Markus Dietlein, Jürgen Wolf, Carsten Kobe	60
18	Early Detection of Erlotinib Treatment Response in NSCLC by 3′-Deoxy-3′-[18F]-Fluoro-L-Thymidine ([18F]FLT) Positron Emission Tomography (PET) 2008 ·PLoS ONE ·Roland T. Ullrich, Thomas Zander, Bernd Neumaier, Mirjam Koker, Takeshi Shimamura, Yannic Waerzeggers, Christa L. Borgman, Samir Tawadros, Hongfeng Li, Martin L. Sos, Heiko Backes, Geoffrey I. Shapiro, Jürgen Wolf, Andreas H. Jacobs, Roman K. Thomas, Alexandra Winkeler	72
19	A cost calculation model for specialist palliative care for patients with non-small cell lung cancer in a tertiary centre 2007 ·Supportive Care in Cancer ·Christoph Ostgathe, (unknown), Jürgen Wolf, Michael Hallek, Raymond Voltz	8
20	Class switch recombination was specifically targeted to immunoglobulin (Ig)G4 or IgA in Hodgkin's disease‐derived cell lines 2001 ·British Journal of Haematology ·Johannes Irsch, Jürgen Wolf, Hans Tesch, Volker Diehl, Andreas Radbruch, Andrea Staratschek‐Jox	12

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact